

CONCORD BIOTECH

General information about company	
Name of The Company	Concord Biotech Limited
BSE Scrip Code	543960
NSE Symbol	CONCORDBIO
MSE Symbol	NA
Date of Start of Financial Year	01-04-2024
Date of End of Financial Year	31-03-2025
Reporting Period	First half yearly
Date of Start of Reporting Period	01-10-2024
Date of End of Reporting Period	31-03-2025
Level of rounding to be used in disclosing related party transactions	Lakhs
Whether the company has any related party?	Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes

(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank's staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	Yes
(III) Whether the company is a 'high value debt listed entity' according to regulation 15 (1A)?	No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?	
(b) If answer to above question is No, please explain the reason for not complying.	
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?	Yes
Latest Date on which RPT policy is updated	29-07-2022
Indicate Company website link for updated RPT policy of the	https://www.concordbiotech.com/public/assets/pdf/Concord-

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)																						
															Additional disclosure of related party transactions - applicable only in case the transaction relates to loans, inter-corporate deposits, advances or investments made by or to the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period in which such transaction was undertaken.							
Sr. No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments				Details of the loans, inter-corporate deposits or investments			
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured
1	Concord Biotech Limited	AAACC8514G	Concord Biotech Japan K.K	ZZZZZ9999Z	Joint Venture	Sale of goods or services		1628.89	As per Companies Act 2013 and approved by Board			1628.89	347.12	1374.15								
2	Concord Biotech Limited	AAACC8514G	Sudhir Vaid	ABVPV9184E	Key Management Personnel	Any other transaction	Lease Rent Paid	69.61	As per Companies Act 2013 and approved by Board			69.61	0	0								
3	Concord Biotech Limited	AAACC8514G	Manju Vaid	ABVPV9191R	Relatives of Key Management Personnel	Any other transaction	Lease Rent Paid	22.34	As per Companies Act 2013 and approved by Board			22.34	0	0								
4	Concord Biotech Limited	AAACC8514G	Col S. K Vaid	ABTPV3630K	Relatives of Key Management Personnel	Any other transaction	Professional Fees	27.71	As per Companies Act 2013 and approved by Board			27.71	2.06	2.06								
5	Concord Biotech Limited	AAACC8514G	Ravi Kapoor & Associates	ABJPK1504D	Enterprises controlled by / under significantly influenced by Directors and/or their relatives:	Any other transaction	Professional Fees	13.75	As per Companies Act 2013 and approved by Board			13.75	4.99	4.99								
6	Concord Biotech Limited	AAACC8514G	Sudhir Vaid	ABVPV9184E	Key Management Personnel	Remuneration		369.75	As per Companies Act 2013 and			369.75	28.75	28.75								

[illegible]

[illegible]